Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
Active, not recruiting · NCT03571633 · Registry updated 2025-11-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer | HER2-positive Breast Cancer; Operable Breast Cancer | Active, not recruiting | Phase 2 | 2025-11-26 | NCT03571633 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
| Centre Leon Berard | 67 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre de Lutte contre le Cancer Jean Perrin | Clermont-Ferrand | France | 2 |
| Centre Hospitalier Annecy Genevois | Pringy | France | 5 |
| Centre Hospitalier Universitaire De Saint Etienne | Saint-Etienne | France | 4 |
| Centre Leon Berard | Lyon | France | 34 |
| CHRU Besançon | Besançon | France | 2 |
| Clinique Charcot | Sainte-Foy-lès-Lyon | France | 1 |
| Groupe hospitalier mutualiste de Grenoble | Grenoble | France | 8 |
| Hopital Prive Jean Mermoz | Lyon | France | 4 |
| Institut Sainte Catherine | Avignon | France | 16 |